cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Beyondspring Inc
16 own
16 watching
Current Price
$1.3
$0.22
(20.37%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
50.7M
52-Week High
52-Week High
3.45
52-Week Low
52-Week Low
0.542
Average Volume
Average Volume
0.17M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization50.7M
icon52-Week High3.45
icon52-Week Low0.542
iconAverage Volume0.17M
iconDividend Yield--
iconP/E Ratio--
What does the Beyondspring Inc do?
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company s lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
Read More
News & Events about Beyondspring Inc.
Globe Newswire
3 months ago
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (BeyondSpring or the Company), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that the first patient has been enrolled in BeyondSprings Phase 2 ...
Globe Newswire
5 months ago
Additional analyses of non-small cell lung cancer (NSCLC) studies support the efficacy of plinabulin monotherapy in reducing the mean duration of severe neutropenia (DSN) for patients receiving docetaxelIn an analysis of breast cancer patients, plinabulin monotherapy was superior vs no treatment for...
PR Newswire
12 months ago
Thinking about buying stock in Nio, Redbox Entertainment, Agora, Chromadex, or Beyondspring? Thinking about buying stock in Nio, Redbox Entertainment, Agora, Chromadex, or Beyondspring? PR Newswire NEW YORK, June 10, 2022 NEW YORK, June 10, 2022 /PRNewswire/ --InvestorsObserverissues critical...
Globe Newswire
1 year ago
NEW YORK, May 27, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the Company or BeyondSpring) (NASDAQ: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have a high unmet medical need, today announced...
Globe Newswire
1 year ago
Paul Friel Elevar Therapeutics today announced the hiring of Paul Friel as chief commercial officer. SALT LAKE CITY, May 23, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who ...
Frequently Asked Questions
Frequently Asked Questions
What is Beyondspring Inc share price today?
plus_minus_icon
Can Indians buy Beyondspring Inc shares?
plus_minus_icon
How can I buy Beyondspring Inc shares from India?
plus_minus_icon
Can Fractional shares of Beyondspring Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Beyondspring Inc stocks?
plus_minus_icon
What is today’s traded volume of Beyondspring Inc?
plus_minus_icon
What is today’s market capitalisation of Beyondspring Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Beyondspring Inc?
plus_minus_icon
What percentage is Beyondspring Inc down from its 52-Week High?
plus_minus_icon
What percentage is Beyondspring Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.3
$0.22
(20.37%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
$1.01
$0.13 (15.15 %)
ALIGOS THERAPEUTICS INC
ALIGOS THERAPEUTICS INC
$1.19
$0.00 (0.00 %)
Passage Bio Inc
Passage Bio Inc
$0.97
$-0.01 (-0.92 %)
Surface Oncology Inc
Surface Oncology Inc
$0.77
$0.00 (0.62 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
$1.01
$0.13 (15.15 %)
ALIGOS THERAPEUTICS INC
ALIGOS THERAPEUTICS INC
$1.19
$0.00 (0.00 %)
Passage Bio Inc
Passage Bio Inc
$0.97
$-0.01 (-0.92 %)
Surface Oncology Inc
Surface Oncology Inc
$0.77
$0.00 (0.62 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00